Coadministration of Dabigatran Etexilate and Atorvastatin
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Dabigatran etexilate, a novel oral direct thrombin inhibitor, has been approved for prophylaxis of thromboembolism in patients undergoing total knee or total hip replacement, and is under clinical investigation for treatment of venous thromboembolism, prevention of stroke in patients with atrial fibrillation, and the treatment of thromboembolic complications following acute coronary syndromes.
To evaluate the potential impact of atorvastatin coadministration on the pharmacokinetics, pharmacodynamics, and safety of dabigatran etexilate.
Healthy male and female volunteers (n = 22) were recruited to this open, randomized, multiple-dose, three-way crossover study. They received dabigatran etexilate 150 mg twice daily on days 1–3 and once daily on day 4, atorvastatin 80 mg once daily on days 1–4, or both treatments together on days 1–4.
Exposure to dabigatran at steady state (area under the drug plasma concentration-time curve at steady state) was reduced by 18% with concomitant atorvastatin administration. An 18% increase in plasma atorvastatin concentration occurred with coadministration of dabigatran etexilate. Exposure to its metabolite 2′-hydroxy-atorvastatin remained essentially unchanged and exposure to 4′-hydroxy-atorvastatin was increased by 15%. The small changes observed are deemed of little clinical relevance given the overall interindividual variability in the metabolism of atorvastatin. Furthermore, there were no changes in the concentrations of active HMG-CoA reductase inhibitors in plasma following dabigatran etexilate coadministration. Six subjects in the atorvastatin treatment group, six subjects during combination treatment, and eight subjects in the dabigatran treatment group reported adverse events. Most of the adverse events reported were nervous system disorders such as dizziness and headache, and general disorders such as fatigue. All adverse events were resolved at the end of the study.
Results of this randomized, open-label, three-way crossover design study in healthy male and female volunteers showed that atorvastatin had no influence on the pharmacokinetic/pharmacodynamic profile of dabigatran, and vice versa, dabigatran etexilate had no impact on the pharmacokinetic/pharmacodynamic profile of atorvastatin. Both drugs were well tolerated when given alone or in combination.
- Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 401S–28S CrossRef
- Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 204S–33S CrossRef
- Hauel NH, Nar H, Priepke H, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002 Apr 25; 45 (9): 1757–66 CrossRef
- Stangier J, Rathgen K, Stahle H. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64 (3): 292–303 CrossRef
- Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005 Jan; 3 (1): 103–11 CrossRef
- Ezekowitz M, Reilly P, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non-valvular atrial fibrillation (PETRO Study). Am J Cardiol 2007 Nov 1; 100 (9): 1419–26 CrossRef
- Caprini JA, Hwang E, Hantel S, et al. The oral direct thrombin inhibitor, dabigatran etexilate, is effective and safe for prevention of major venous thromboembolism following major orthopedic surgery [abstract no. OW050]. XXIst Congress of the ISTH; 2007 Jul 6–12; Geneva
- Eriksson B, Dahl O, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non inferiority trial. Lancet 2007; 370: 949–56 CrossRef
- Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003; 42 (13): 1141–60 CrossRef
- Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47 (15): 285–95 CrossRef
- Williams RL, Mamelok RD. Hepatic disease and drug pharmacokinetics. Clin Pharmacokinet 1980 Nov–Dec; 5 (6): 528–47 CrossRef
- Corsini A, Bellosta S. Drug-drug interactions with statins. Expert Rev Clin Pharmacol 2008; 1 (1): 105–13 CrossRef
- Kostapanos MS, Liberopoulos EN, Goudevenos JA, et al. Do statins have an antiarrhythmic activity? Cardiovasc Res 2007; 75 (1): 10–20 CrossRef
- Coadministration of Dabigatran Etexilate and Atorvastatin
American Journal of Cardiovascular Drugs
Volume 9, Issue 1 , pp 59-68
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors